

# Giandomenico Roviello

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/241403/giandomenico-roviello-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192  
papers

2,190  
citations

24  
h-index

40  
g-index

220  
ext. papers

2,915  
ext. citations

4.2  
avg, IF

5.34  
L-index

#	Paper	IF	Citations
192	Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. <i>British Journal of Surgery</i> , <b>2018</b> , 105, 159-167	5.3	123
191	Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 496-508	8.8	117
190	The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. <i>Gastric Cancer</i> , <b>2017</b> , 20, 20-30	7.6	110
189	Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. <i>Cancer Letters</i> , <b>2016</b> , 372, 187-91	9.9	100
188	Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. <i>Cells</i> , <b>2019</b> , 8,	7.9	70
187	Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 943-50	3.1	70
186	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , <b>2017</b> , 75, 245-258	7.5	66
185	Surgical management of advanced gastric cancer: An evolving issue. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 18-27	3.6	54
184	c-Met targeting in advanced gastric cancer: An open challenge. <i>Cancer Letters</i> , <b>2015</b> , 365, 30-6	9.9	51
183	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , <b>2019</b> , 15, 2423-2433	3.6	48
182	The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. <i>Journal of Cellular Biochemistry</i> , <b>2018</b> , 119, 4287-4292	4.7	43
181	Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. <i>Gastric Cancer</i> , <b>2016</b> , 19, 31-41	7.6	42
180	Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. <i>Tumor Biology</i> , <b>2017</b> , 39, 1010428317695023	2.9	41
179	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , <b>2016</b> , 61, 111-21	7.5	41
178	Apatinib for the treatment of gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 887-92	4.2	38
177	Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. <i>Cells</i> , <b>2018</b> , 7,	7.9	32
176	CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. <i>Cancer Investigation</i> , <b>2012</b> , 30, 65-71	2.1	31

175	MSI and EBV Positive Gastric Cancer <sup>B</sup> Subgroups and Their Link With Novel Immunotherapy. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	30
174	Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?. <i>Clinical and Experimental Medicine</i> , <b>2018</b> , 18, 15-20	4.9	30
173	Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 101, 12-20	7	30
172	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , <b>2017</b> , 34, 119	3.7	26
171	Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 102, 82-8	7	26
170	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , <b>2020</b> , 40, 704-711	7.9	25
169	Role of ATP-binding cassette transporters in cancer initiation and progression. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 60, 72-95	12.7	24
168	Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 941-7	3.5	22
167	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 257-265	7.5	21
166	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. <i>International Journal of Hyperthermia</i> , <b>2016</b> , 32, 298-310	3.7	21
165	Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919861905	5.4	21
164	No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 1135-40	3.5	21
163	KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status. <i>Pathology and Oncology Research</i> , <b>2019</b> , 25, 333-340	2.6	21
162	PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. <i>Tumor Biology</i> , <b>2014</b> , 35, 10601-7	2.9	18
161	Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. <i>Cancers</i> , <b>2020</b> , 12,	6.6	18
160	Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 683-90	3.5	17
159	Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. <i>Medical Oncology</i> , <b>2015</b> , 32, 52	3.7	17
158	Methylene Blue-Current Knowledge, Fluorescent Properties, and Its Future Use. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	17

157	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. <i>Immunotherapy</i> , <b>2021</b> , 13, 621-631	3.8	16
156	Tumor-Agnostic Treatment for Cancer: When How is Better than Where. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 519-527	3.2	16
155	Molecular key to understand the gastric cancer biology in elderly patients-The role of microsatellite instability. <i>Journal of Surgical Oncology</i> , <b>2017</b> , 115, 344-350	2.8	15
154	Is there still a place for docetaxel rechallenge in prostate cancer?. <i>World Journal of Clinical Oncology</i> , <b>2015</b> , 6, 99-103	2.5	15
153	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>Translational Oncology</i> , <b>2020</b> , 13, 100795	4.9	14
152	Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas. <i>Tumor Biology</i> , <b>2016</b> , 37, 1959-66	2.9	14
151	Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 1133-1137	4.3	14
150	Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. <i>Prostate Cancer</i> , <b>2011</b> , 2011, 258689	1.9	14
149	Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. <i>Medical Oncology</i> , <b>2015</b> , 32, 134	3.7	12
148	The distinctive nature of adenocarcinoma of the lung. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 2399-406	4.4	12
147	Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. <i>Molecular Biology Reports</i> , <b>2019</b> , 46, 2713-2720	2.8	11
146	Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, e229-34	4.9	11
145	The third line of treatment for metastatic prostate cancer patients: Option or strategy?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 265-71	7	11
144	Re: Silke Gillissen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>Eur Urol</i> 2018;73:178-211. <i>European Urology</i> , <b>2018</b> , 73, e31	10.2	11
143	Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis. <i>CardioVascular and Interventional Radiology</i> , <b>2018</b> , 41, 1840-1848	2.7	11
142	Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219566	3.7	11
141	Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 22332-22339	3.3	11
140	Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	11

139	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1102	5.3	11
138	Hyperthermic intraperitoneal chemotherapy for the treatment of ovarian cancer: A brief overview of recent results. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 297-305	7	10
137	Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients. <i>Molecular and Cellular Oncology</i> , <b>2020</b> , 7, 1788366	1.2	10
136	No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 334-340	4.9	10
135	Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1033-1039	3.6	10
134	Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. <i>Cancer Investigation</i> , <b>2017</b> , 35, 187-194	2.1	9
133	Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis. <i>Investigational New Drugs</i> , <b>2017</b> , 35, 518-523	4.3	9
132	Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 669-677	3.5	9
131	The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients. <i>Surgical Innovation</i> , <b>2018</b> , 25, 99-104	2	9
130	TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 152, 103011	7	8
129	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. <i>Tumor Biology</i> , <b>2016</b> , 37, 127-40	2.9	8
128	Avelumab in gastric cancer. <i>Immunotherapy</i> , <b>2019</b> , 11, 759-768	3.8	8
127	Advances in anti-BRAF therapies for lung cancer. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 879-890	4.3	8
126	Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study. <i>Medicine (United States)</i> , <b>2018</b> , 97, e10745	1.8	8
125	Gut Microbiota Modulation in the Context of Immune-Related Aspects of spp. and spp. in Gastrointestinal Cancers. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	8
124	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
123	Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. <i>Breast</i> , <b>2019</b> , 46, 19-24	3.6	7
122	Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 1274-1288	4.3	7

121	Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 441-6	3.3	7
120	Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. <i>Medical Oncology</i> , <b>2018</b> , 35, 29	3.7	7
119	A Phase II study of olaparib in breast cancer patients: biological evaluation from a window of opportunity trial. <i>Future Oncology</i> , <b>2016</b> , 12, 2189-93	3.6	7
118	Evolution and emerging future of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence. <i>International Journal of Hyperthermia</i> , <b>2016</b> , 32, 173-9	3.7	7
117	Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , <b>2014</b> , 25, 472-7	2.4	7
116	Isolated Testicular Metastasis from Prostate Cancer. <i>American Journal of Case Reports</i> , <b>2017</b> , 18, 887-889	3.3	7
115	Corticosteroid switch after progression on abiraterone acetate plus prednisone. <i>International Journal of Clinical Oncology</i> , <b>2020</b> , 25, 240-246	4.2	7
114	Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 1110-1115	4.3	7
113	The gut microbiome and efficacy of cancer immunotherapy. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 231, 107973	13.9	7
112	Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?. <i>Immunotherapy</i> , <b>2017</b> , 9, 25-32	3.8	6
111	Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged $\geq 75$ years with impaired performance status. <i>Journal of Geriatric Oncology</i> , <b>2015</b> , 6, 380-6	3.6	6
110	Lenvatinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 507-512	5.9	6
109	Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 1139-1146	3.8	6
108	Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 9-13	4.4	6
107	Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 165, 103434	7	6
106	Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 439-45	3.5	5
105	Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 883-8	4.6	5
104	Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 5692317	4.5	5

103	Targeted Therapies for Prostate Cancer. <i>Cancer Investigation</i> , <b>2015</b> , 33, 276-85	2.1	5
102	Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma. <i>Journal of the American Geriatrics Society</i> , <b>2014</b> , 62, 2204-5	5.6	5
101	Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification. <i>Cancer Investigation</i> , <b>2017</b> , 35, 325-332	2.1	4
100	Cabozantinib as a second-line treatment option in hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 623-629	3.8	4
99	Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 3811-3815	4.4	4
98	Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma. <i>Research and Reports in Urology</i> , <b>2017</b> , 9, 65-69	1.3	4
97	Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience. <i>Anti-Cancer Drugs</i> , <b>2015</b> , 26, 884-7	2.4	4
96	Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 78870-78881	3.3	4
95	Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis-what is currently known?. <i>Gastric Cancer</i> , <b>2021</b> , 1	7.6	4
94	Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. <i>Current Cancer Drug Targets</i> , <b>2020</b> , 20, 887-895	2.8	4
93	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 19281	4.9	4
92	Electronic nicotine delivery systems (ENDS): not still ready to put on END. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 3857-3865	2.6	4
91	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. <i>Gastric Cancer</i> , <b>2021</b> , 24, 765-779	7.6	4
90	Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 632256	5.3	4
89	Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4636	1.8	4
88	A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers. <i>Clinical Breast Cancer</i> , <b>2016</b> , 16, e57-9	3	4
87	Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1270-1272	21.7	4
86	Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	4

85	Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 113, 18-21	7	3
84	FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 10271-10278	3.6	3
83	TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluoropyrimidine drug combination. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 152, 102987	7	3
82	An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRC). <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 149, 102921	7	3
81	Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
80	Perioperative chemotherapy for gastric cancer in FLOT4. <i>Lancet, The</i> , <b>2020</b> , 395, e3	40	3
79	Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. <i>Breast</i> , <b>2016</b> , 29, 55-61	3.6	3
78	Apatinib in metastatic gastric cancer: can paclitaxel make the difference?. <i>Anti-Cancer Drugs</i> , <b>2016</b> , 27, 809	2.4	3
77	Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient. <i>Anti-Cancer Drugs</i> , <b>2016</b> , 27, 470-3	2.4	3
76	How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue. <i>Tumor Biology</i> , <b>2014</b> , 35, 7391-2	2.9	3
75	PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy. <i>EBioMedicine</i> , <b>2017</b> , 22, 18-19	8.8	3
74	Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival. <i>Anti-Cancer Drugs</i> , <b>2015</b> , 26, 910-1	2.4	3
73	Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer. <i>International Journal of Biological Markers</i> , <b>2013</b> , 28, 326-8	2.8	3
72	A husband and a wife with simultaneous presentation of glioblastoma multiforme: a case report. <i>Case Reports in Oncology</i> , <b>2013</b> , 6, 538-43	1	3
71	Current status and future perspectives in HER2 positive advanced gastric cancer.. <i>Clinical and Translational Oncology</i> , <b>2022</b> , 1	3.6	3
70	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , <b>2021</b> , 32, 159-167	4.7	3
69	Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?. <i>Current Cancer Drug Targets</i> , <b>2016</b> , 16, 209-14	2.8	3
68	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 682449	5.3	3



67	High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 1817-24	4.9	3
66	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. <i>Immuno</i> , <b>2021</b> , 1, 253-263		3
65	Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer. <i>Anticancer Research</i> , <b>2015</b> , 35, 3097-102	2.3	3
64	The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 524-530	4.3	2
63	Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 493-7	4.6	2
62	Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer. <i>Anti-Cancer Drugs</i> , <b>2020</b> , 31, 632-636	2.4	2
61	Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2016.02.035">http://dx.doi.org/10.1016/j.eururo.2016.02.035</a> : Corticosteroid-associated Adverse Events in	10.2	2
60	Familial aggregation of gastric cancer with microsatellite instability. <i>Acta Chirurgica Belgica</i> , <b>2018</b> , 118, 287-293	0.9	2
59	Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer. <i>Medicine (United States)</i> , <b>2014</b> , 93, e163	1.8	2
58	Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis. <i>Medical Oncology</i> , <b>2017</b> , 34, 166	3.7	2
57	Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?. <i>Future Oncology</i> , <b>2017</b> , 13, 2473-2477	3.6	2
56	Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study. <i>Anti-Cancer Drugs</i> , <b>2015</b> , 26, 878-83	2.4	2
55	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 1-7	3.5	2
54	NTRK Gene Fusion Detection in Atypical Spitz Tumors. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
53	p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. <i>Molecules</i> , <b>2021</b> , 26,	4.8	2
52	Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. <i>Therapeutic Advances in Urology</i> , <b>2021</b> , 13, 17562872211053189	3.2	2
51	Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. <i>Anti-Cancer Drugs</i> , <b>2015</b> , 26, 682-6	2.4	2
50	Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. <i>Endocrine</i> , <b>2021</b> , 74, 172-179	4	2

49	New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 108, 62-68	7	2
48	Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel. <i>Anti-Cancer Drugs</i> , <b>2019</b> , 30, e0789	2.4	2
47	Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2019</b> , 34, 141-146	3.9	2
46	Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	2
45	An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1720-5	4.6	1
44	Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer. <i>Future Oncology</i> , <b>2015</b> , 11, 2563-74	3.6	1
43	Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. <i>International Reviews of Immunology</i> , <b>2020</b> , 39, 223-232	4.6	1
42	Radiotherapy after prostatectomy in high-risk prostate cancer. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 2139-2140	3.6	1
41	Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2131-2133	10.3	1
40	Baseline and early change of systemic inflammation index (bSII and SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5072-5072	2.2	1
39	Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 691-691	2.2	1
38	Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma. <i>Lung Cancer</i> , <b>2017</b> , 114, 103-105	5.9	1
37	Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. <i>Journal of Oncology</i> , <b>2020</b> , 2020, 8024124	4.5	1
36	Second line of treatment for HER2-positive gastric cancer: an evolving issue. <i>Reports of Practical Oncology and Radiotherapy</i> , <b>2021</b> , 26, 316-317	1.5	1
35	Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
34	Maintenance in gastric cancer: New life for an old issue?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 160, 103307	7	1
33	ALERTASTE: improving food pleasure and intake of oncology patients receiving chemotherapy. <i>Future Oncology</i> , <b>2021</b> , 17, 2573-2579	3.6	1
32	Immunotherapy-based combinations versus standard first-line and hypothyroidism risk. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1664-1665	3.6	1

31	Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 83-86	3.3	1
30	A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 401-401	2.2	1
29	The effects of hepatitis B virus infection on natural and IVF pregnancy: A meta-analysis study. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1234-1245	3.4	1
28	Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
27	Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?. <i>Therapeutic Advances in Urology</i> , <b>2021</b> , 13, 17562872211029784	3.2	1
26	To surrogate or not surrogate: an ancient dilemma without a happy ending. <i>Journal of Hospital Management and Health Policy</i> , <b>2019</b> , 3, 6-6	0.5	0
25	Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis. <i>European Urology</i> , <b>2017</b> , 72, 1027-1028	10.2	0
24	Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 371-375	3.3	0
23	Gastric and colonic metastasis from NSCLC: A very unusual case report.. <i>Medicine (United States)</i> , <b>2022</b> , 101, e28249	1.8	0
22	Darolutamide in hormone-sensitive and castration-resistant prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 535-544	3.8	0
21	Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 229, 107924	13.9	0
20	Comparing immunotherapies to other frequently used treatments of gastric cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 1221-1232	3.8	0
19	Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 1353-1365	3.8	0
18	Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 320-320	2.2	0
17	Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 328	8.5	0
16	NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities.. <i>Pathology and Oncology Research</i> , <b>2022</b> , 28, 1610237	2.6	0
15	Therapeutic management of a symptomatic Kaposi's sarcoma patient with renal failure undergoing haemodialysis: A case report.. <i>Dermatology Reports</i> , <b>2022</b> , 14, 9113	0.9	0
14	The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer.. <i>Scientific Reports</i> , <b>2022</b> , 12, 8244	4.9	0

- 13 Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality?. *AME Medical Journal*, **2019**, 4, 24-24 1
- 12 New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When. *Clinical Genitourinary Cancer*, **2019**, 17, e534-e535 3.3
- 11 In reply to Egger et al.: Lack of benefit from adjuvant postoperative radiotherapy and issues raised about upfront management of high- and very-high-risk prostate cancer patients. *Journal of Medical Imaging and Radiation Oncology*, **2020**, 64, 595-596 1.7
- 10 Meet Our Associate Editorial Board Member. *Current Clinical Pharmacology*, **2018**, 12, 201-201 2.5
- 9 Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience. *Reports of Practical Oncology and Radiotherapy*, **2018**, 23, 298-299 1.5
- 8 Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?. *Medicine (United States)*, **2019**, 98, e16249 1.8
- 7 The relationship between KLK3 rs17632542 and PRNCR1 rs16901979 polymorphisms with susceptibility to prostate cancer. *Meta Gene*, **2019**, 21, 100595 0.7
- 6 Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2016.06.033>. *European Urology*, **2017**, 71, e55 10.2
- 5 Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14).. *Journal of Clinical Oncology*, **2020**, 38, e17093-e17093 2.2
- 4 Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O):A real-world study on behalf of Meet-URO group (MeetUro-7b).. *Journal of Clinical Oncology*, **2020**, 38, e17088-e17088 2.2
- 3 How the CARD trial has changed the cards on the table for metastatic castration resistant prostate cancer. *Reports of Practical Oncology and Radiotherapy*, **2020**, 25, 701-702 1.5
- 2 EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 2301-2307 4.9
- 1 Meet Our Associate Editorial Board Member. *Current Pharmaceutical Biotechnology*, **2018**, 19, 683-683 2.6